Page 2 - Evaluate Vantage News Today : Breaking News, Live Updates & Top Stories | Vimarsana

INN takes a closer look at the first half of 2021 for the biotech industry and the key trends investors need to know about so far this year.

BioPharma

Wednesday, 20 January 2021, 4:03 pm The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the lion's share of 2021 vaccine sales. According to data presented by Finaria.it, BioNTech-Pfizer and Moderna COVID-19 vaccines sales are expected to generate $14.7bn in revenue by 2023. Moderna COVID-19 Vaccine Sales Revenue to hit $3.5B in 2021 The call for COVID-19 vaccines and treatments has become louder than ev...

Press Release – Psychic Ventures Ltd The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the …The year 2021 is set to become quite a year for the pharma companies leading the COVID-19 vaccine race, with significant revenues on the line. As some of the most significant players in the market, pharma giants Pfizer and Moderna are set for the lion’s share of 2021 vaccine sales. According to data presen...

Evaluate Ltd.: Evaluate Vantage 2021 Preview: High Hopes and Valuations Set the Tone for Biopharma Evaluate Vantage 2021 Preview, published today Sales of COVID-19 vaccines are expected to reach between $10-15bn next year, and for now Moderna's mRNA-1237 is the favored candidate among equity analysts, despite BioNTech and Pfizer's first mover advantage. With many leading COVID-19 projects due to yield data next year, it should become clearer which companies will deliver clinically and commercially successful pandemic products. Across the broader industry, oncology continues to be a major driv...